Halozyme Therapeutics (HALO) Tops Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.62 +0.91%
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $39 million versus the consensus estimate of $38.37 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
